ScreenerHero

IMRX Immuneering Corporation

NAS · US · Healthcare · Biotechnology · immuneering.com
3.860USD+0.78%Mkt Cap: 249.73M $P/E: —

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a P…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap249.73M USD
Enterprise Value101.52M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-56.02M USD
Revenue/Share—
Last Price3.860 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees57
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.05
PEG—
EV/EBITDA-1.61
EV/Revenue—
P/S—
P/B1.30
EPS (TTM)-0.88
EPS (Forward)-1.26
52W Range
3.7402% of range9.600
52W High9.600 USD
52W Low3.740 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-25.64%
ROA-24.15%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-45.34M USD
CapEx (TTM)142.23K USD
FCF Margin—
FCF Yield-15.76%
Net Debt-146.27M USD
Net Debt/EBITDA2.32
Balance Sheet
Debt/Equity0.02
Current Ratio19.47
Quick Ratio18.47
Book Value/Sh2.95 USD
Cash/Share2.32 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)17.17 USD
Upside (mean)+344.7%
Target Range12.00 USD – 30.00 USD
12.00+344.7% to mean30.00
# Analysts6
Ownership
Shares Out.64.70M
Float49.21M
Insiders13.83%
Institutions55.44%
Short Interest
Short Ratio23.8d
Short % Float31.68%
Short % Out.24.04%
Shares Short15.55M
Short (prev mo.)14.43M
Technical
SMA 504.623 (-16.5%)
SMA 2005.017 (-23.1%)
Beta0.46
S&P 52W Chg16.45%
Avg Vol (30d)659.97K
Avg Vol (10d)562.07K
Technical Indicators
RSI (14)30.5
MACD-0.2134
MACD Signal-0.1686
MACD Hist.-0.0447
BB Upper4.804 USD
BB Middle4.287 USD
BB Lower3.769 USD
BB Width24.15%
ATR (14)0.1912 USD
Vol Ratio (20d)1.05x